Ask AI

Managing Bispecific Antibody-Related Toxicities in Your Patients With Multiple Myeloma: Interdisciplinary Guidance and Care Coordination for Community HCPs

Start Activity
Text Module
Text Module Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: August 18, 2026

Expiration: February 17, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Text Module 3 Post Assessment 4 Evaluation 5 Credit

This text-based activity examines the expanding use of bispecific antibodies in relapsed/refractory multiple myeloma, including toxicity management and REMS compliance. Expert faculty also reviews key adverse event management issues, particularly CRS, ICANS, infection risk, and GPRC5D-associated on-target/off-tumor effects, and discusses evolving approaches, such as dexamethasone-first CRS management, prophylactic tocilizumab, infection prophylaxis, and outpatient or hybrid administration models. These considerations are clinically important because effective use of bispecific antibodies requires learners to balance strong antimyeloma efficacy with proactive monitoring, multidisciplinary coordination, and individualized supportive care to improve safety and expand access across academic and community practice settings.

Jessica McElwee
Jessica McElwee, PharmD, BCOP
BsAbs in RRMM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
Begin Your Text Module
1.

How many people with multiple myeloma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

After step-up dose 2 with talquetamab, a 69-year-old male patient with multiple myeloma has a fever (100.9°F), and is experiencing mild dizziness, some sweating, unusual fatigue, trouble concentrating and his oxygen saturation is at 94%. Based on this information, you hold talquetamab and consult on what to do next.

What else is appropriate for managing the patient?

4.

A 70-year-old man successfully completed step-up dosing of teclistamab at an academic center and is transitioning care to his local oncologist. He experienced grade 2 CRS after step-up dose 2, which resolved with acetaminophen, IV fluids, and a single dose of tocilizumab. He has had no further CRS or immune effector cell–associated neurotoxicity syndrome (ICANS). His labs show: absolute neutrophil count 2100/µL, IgG 398 mg/dL, CD4+ cell count 194 cells/µL.

Which of the following is the most important care coordination consideration to address prior to transitioning care?

Begin Your Text Module